Stewart C Allison, Byers Lauren Averett
Department of Thoracic and Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Thoracic and Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer Cell. 2015 Jul 13;28(1):4-6. doi: 10.1016/j.ccell.2015.06.011.
In this issue of Cancer Cell, Mohammad et al. describe LSD1, a histone demethylase, as a therapeutic target in SCLC with a unique epigenetic signature to predict drug sensitivity. Inhibition of LSD1 reduces cell proliferation and stem cell maintenance while promoting cell differentiation and reducing tumor growth in preclinical models.
在本期《癌细胞》杂志中，穆罕默德等人将组蛋白去甲基化酶LSD1描述为小细胞肺癌（SCLC）中的一个治疗靶点，它具有独特的表观遗传特征来预测药物敏感性。在临床前模型中，抑制LSD1可减少细胞增殖和干细胞维持，同时促进细胞分化并降低肿瘤生长。
